Gay, F., Roeloffzen, W., Dimopoulos, M. A., Rosiñol, L., Klift, M. V. D., Oriol, A., Katodritou, E., Wu, K., Rodriguez-Otero, P., Hajek, R., Leeuwen-Segarceanu, E. M. V., Zamagni, E., Donk, N. W. V. D., Weisel, K. C., Schjesvold, F., Bladé, J., Einsele, H., Sonneveld, P., Boccadoro, M., Broijl, A. (2025). Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7502